Ciclesonide Market Demands and Growth Prediction, Outlook 2018-2026 With Top Vendors AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc

Ciclesonide is an inhaled corticosteroids (ICS), recommended in asthma and chronic obstructive pulmonary disease (COPD) indication to get relief from difficulty in breathing, chest tightness, wheezing, and coughing. Inhaled drugs including inhaled corticosteroids, long acting β2 adrenoceptor agonists (LABA), and long acting muscarinic receptor antagonists (LAMA) are important treatment regime in the management of COPD. Inhaled corticosteroids are generally considered as safe and well tolerated in both adults and children. The improved safety and comparable efficacy profiles of ciclesonide demonstrated a potential treatment option which may lead to improved adherence and treatment outcome in asthma and COPD.

Request Customization of This Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/2291

Market Dynamics

Factors such as high prevalence of allergy rhinitis and asthma, and frequent product approval and launches in key regions are expected to drive the market growth over the forecast period. For instance, according to the Global Asthma Report published in 2018, it was estimated that globally asthma kills around 1,000 people every day and affects as many as 339 million people, worldwide. Furthermore, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol indicated for treatment of allergic rhinitis and launched it in the U.S. market.

Moreover, increasing strategic mergers and acquisitions by key players is also expected to support and drive the market growth. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).

High Prevalence of Allergy Rhinitis and Asthma is Expected to Augment the Market Growth

Ciclesonide is widely used in the treatment of asthma and allergy rhinitis. Allergy rhinitis and asthma are very common conditions and prevalence of these two disease is very high in countries such as the U.S., U.K., China, and India. Hence, high prevalence of allergy rhinitis is expected to drastically increase demand for ciclesonide and drive its market growth over forecast period. According to the Global Asthma Report published in 2018, an asthma kills around 1,000 people every day and affects as many as 339 million people worldwide. Prevalence of asthma is rising and people in low- and middle-income countries suffer the most.

Competitive Landscape

Some of the key players operating in the ciclesonide market include AstraZeneca Plc., Cipla Limited, Sun Pharmaceutical Industries Ltd., and Apotex Inc.

Download PDF Brochure of The Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2291

Ciclesonide is indicated for the treatment and management of allergy rhinitis and asthma. However, availability of some other medication offering better treatment regime are indicated for the treatment of allergy rhinitis and asthma. This is expected to create competition and hinder the adoption of ciclesonide over the forecast period. For instance, GlaxoSmithKline Plc’s drug, namely Veramyst (fluticasone furoate) Nasal Spray is indicated for the treatment of seasonal and perennial allergic rhinitis. NASONEX (mometasone furoate monohydrate) Nasal Spray by Merck & Co., Inc. is indicated for treatment of nasal symptoms of allergic rhinitis.

Furthermore, patent expiration and subsequent launch of generic ciclesonide in the market could hamper growth of ciclesonide in the near future.

With the expiry of branded ciclesonide products such as OMNARIS Nasal Spray and ALVESCO it is expected that generic manufacturers will enter the market. Launch of generic versions of ciclesonide will increase competition and will restrain growth of the market in terms of revenue as generic products are available in less price. For instance, according to the data published in Sepracor Inc. annual report, OMNARIS Nasal Spray and ALVESCO HFA lost their patent in October 2017. Thus, patent lose can affect and hinder the market growth in terms of revenue.

Ask For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2291

North America is expected to hold a dominate position in global ciclesonide market in 2017, owing to high prevalence of allergy rhinitis and asthma conditions and increasing drug launches in this region. For instance, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its Zetonna (ciclesonide) nasal aerosol for the treatment of allergic rhinitis and launched it in the U.S. market. Furthermore, according to the data published by American Academy of Allergy Asthma & Immunology, in 2016 around 8.3% of children in the U.S. suffered from asthma.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.